SML0284

Mycophenolate mofetil

Name: Mycophenolate mofetil
Brand: SIGMA

≥98% (HPLC), Mycophenolic acid prodrug, powder

別名:

(4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester, RS 61443, TM-MMF

ログインで組織・契約価格をご覧ください。

サイズを選択してください

この商品について

実験式（ヒル表記法）:

C₂₃H₃₁NO₇

CAS番号:

128794-94-5

分子量:

433.49

UNSPSC Code:

12352200

PubChem Substance ID:

329825292

NACRES:

NA.77

MDL number:

MFCD00867568

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

主要文書

すべての文書を表示

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

製品名

Mycophenolate mofetil, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: ≥15 mg/mL

storage temp.

room temp

SMILES string

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN3CCOCC3

InChI

1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+

InChI key

RTGDFNSFWBGLEC-SYZQJQIISA-N

Gene Information

human ... IMPDH1(3614), IMPDH2(3615)

類似した製品をお探しですか？訪問製品比較ガイド

Application

Mycophenolate mofetil has been used to treat wild-type embryos for inhibiting nucleotide synthesis.

Biochem/physiol Actions

Mycophenolate mofetil is a prodrug of mycophenolic acid (Cat. # M5255) that is cleaved by nonspecific esterases in vivo to produce the parent compound. Mycophenolic acid blocks inosine monophosphate dehydrogenase and is a potent immunosuppresive agent.

Mycophenolate mofetil is a prodrug of mycophenolic acid and potent immunosuppresive agent.

Mycophenolate mofetil functions as a rate-limiting enzyme in de novo synthesis of guanosine nucleotides.

pictograms

GHS08,GHS07,GHS09

signalword

Danger

hcodes

H302,H360D,H372,H410

pcodes

P202 - P260 - P264 - P273 - P301 + P312 - P308 + P313

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 1

保管分類

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

SML0284-BULK: + SML0284-50MG: + SML0284-VAR: + SML0284-10MG:

jan

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

0000337757

0000124275

0000124274

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

COAを検索

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Mycophenolate mofetil and its mechanisms of action

Allison AC and Eugui EM

Immunopharmacology, 47(2-3), 85-118 (2000)

Additive reductions in zebrafish PRPS1 activity result in a spectrum of deficiencies modeling several human PRPS1-associated diseases.

Wuhong Pei et al.

Scientific reports, 6, 29946-29946 (2016-07-19)

Phosphoribosyl pyrophosphate synthetase-1 (PRPS1) is a key enzyme in nucleotide biosynthesis, and mutations in PRPS1 are found in several human diseases including nonsyndromic sensorineural deafness, Charcot-Marie-Tooth disease-5, and Arts Syndrome. We utilized zebrafish as a model to confirm that mutations

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Eduardo F Mysler et al.

Arthritis and rheumatism, 65(9), 2368-2379 (2013-06-07)

To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). Patients were randomized 1:1:1 to receive placebo, 400 mg ocrelizumab, or 1,000 mg ocrelizumab given as an intravenous infusion on days 1 and 15

Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.

K Budde et al.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 14(12), 2796-2806 (2014-10-04)

This Phase III randomized trial examined efficacy and safety of a novel once-daily extended-release tacrolimus formulation (LCP-Tacro [LCPT]) versus twice-daily tacrolimus in de novo kidney transplantation. Primary efficacy end point was proportion of patients with treatment failure (death, graft failure

Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin.

Christopher J Yates et al.

Transplantation, 96(8), 726-731 (2013-08-02)

The sensitivity of fasting plasma glucose (FPG) in screening for new-onset diabetes after transplantation (NODAT) has been questioned, particularly in the presence of moderate-dose prednisolone, where peak plasma glucose occurs 7 to 8 hr after administration. Oral glucose tolerance testing

Mycophenolate mofetil

≥98% (HPLC), Mycophenolic acid prodrug, powder

サイズを選択してください

この商品について

主要文書

特性

製品名

Quality Level

assay

form

color

solubility

storage temp.

SMILES string

InChI

InChI key

Gene Information

関連するカテゴリー

詳細

Application

Biochem/physiol Actions

安全性情報

pictograms

signalword

hcodes

pcodes

Hazard Classifications

保管分類

wgk

flash_point_f

flash_point_c

適用法令

SML0284-BULK: + SML0284-50MG: + SML0284-VAR: + SML0284-10MG:

資料

試験成績書（COA）

以前この製品を購入いただいたことがある場合

参考文献

テクニカルサービス